Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts broadly rate Medpace “Hold”: Eleven of 13 covering brokerages issued hold ratings, while two recommended buying the stock. The average 12-month price target is approximately $584.18.
• Medpace exceeded quarterly expectations: The company reported $4.25 in EPS and $707.33 million in revenue, surpassing estimates of $3.98 and $689.51 million, respectively. Revenue increased 17.2% year over year.
• Shares and insider activity remain notable: MEDP opened at $590.67, with a 52-week range of $373.00 to $677.90, while insiders sold roughly $16.2 million worth of shares over the past 90 days.

Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) has been given a consensus recommendation of "Hold" by the thirteen brokerages that are covering the stock, Marketbeat Ratings reports. Eleven investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $584.1818.

Several brokerages have weighed in on MEDP. Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a report on Friday, July 24th. Weiss Ratings restated a "hold (c+)" rating on shares of Medpace in a research report on Thursday, July 2nd. Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Finally, Leerink Partners set a $620.00 price objective on shares of Medpace in a research report on Thursday, July 23rd.

Medpace Stock Performance

NASDAQ:MEDP opened at $590.67 on Monday. The firm has a market capitalization of $16.49 billion, a PE ratio of 34.62, a price-to-earnings-growth ratio of 2.63 and a beta of 1.15. The stock has a 50 day moving average of $522.14 and a 200-day moving average of $491.95. Medpace has a 52 week low of $373.00 and a 52 week high of $677.90.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. The business's revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace will post 17.54 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 7,500 shares of Medpace stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president directly owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 31,087 shares of company stock worth $16,203,054. 20.50% of the stock is owned by company insiders.

Institutional Trading of Medpace

Several large investors have recently added to or reduced their stakes in MEDP. California State Teachers Retirement System boosted its position in Medpace by 22.1% during the 1st quarter. California State Teachers Retirement System now owns 26,042 shares of the company's stock worth $12,505,000 after acquiring an additional 4,719 shares during the period. Cerity Partners LLC increased its holdings in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company's stock valued at $45,478,000 after purchasing an additional 23,530 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in shares of Medpace by 24,930.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company's stock worth $56,936,000 after purchasing an additional 100,968 shares in the last quarter. Mitchell Capital Management Co. purchased a new stake in shares of Medpace in the fourth quarter worth approximately $3,383,000. Finally, M&T Bank Corp lifted its position in shares of Medpace by 1,596.0% in the fourth quarter. M&T Bank Corp now owns 14,128 shares of the company's stock worth $7,935,000 after purchasing an additional 13,295 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source